Pharmacogenomics-assisted treatment versus standard of care in schizophrenia: a systematic review and meta-analysis.

ABSTRACT:

Background

Pharmacogenomic (PGx) factors significantly influence how patients respond to antipsychotic medications This systematic review was performed to synthesize the clinical utility of PGx-assisted treatment versus standard of care in schizophrenia.

Methods

PubMed, Embase, and Cochrane CENTRAL databases were searched for randomized controlled trials (RCTs) from inception till June 2024 that had compared the clinical utility of PGx-assisted intervention as compared to the standard of care in schizophrenia. The primary outcome was safety, and the secondary outcomes were efficacy and medication adherence. Pooled standardized mean differences (SMD) along with a 95% confidence interval (CI) were calculated (random-effects model) wherever feasible.

Results

A total of 1

SUBMITTER: Das S 

PROVIDER: S-EPMC11463053 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature